Veeda provides contract research organization services for clinical trials and drug development.
$90MVenture
A $90M Series round for a CRO signals that Khosla sees outsourced clinical ops as a bottleneck worth attacking—likely betting on automation, data infrastructure, or geographic arbitrage to compress trial timelines. If you're building in biotech tooling, pharma ops, or even regulatory tech, this validates that buyers will pay for anything that de-risks or accelerates the clinical path, not just the science itself.